.png
)
PHARMINHO | Regulatory Briefing
Compliance Advisory
Dated: 30 July 2026
Effective: 5 August 2026
Drugs (Eleventh Amendment) Rules 2026: CDSCO Introduces Formal Debarment for Fake or Fabricated Documents
For the first time, the Drugs Rules, 1945 carry a codified debarment mechanism — allowing Licensing Authorities to bar an applicant, for a defined period or permanently, on a finding that misleading, fake, or fabricated documents or information were submitted in support of a licence application.
The Ministry of Health and Family Welfare has notified the Drugs (Eleventh Amendment) Rules, 2026 vide G.S.R. 706(E), dated 30 July 2026, inserting a formal definition of “debarment” into Rule 2 of the Drugs Rules, 1945, and a corresponding debarment provision into seven separate Parts of the Rules. The rules came into force on 5 August 2026, the date of Gazette publication.
01Background
This amendment did not emerge without notice. A draft of these rules was first published under the proviso to Section 12(1) and Section 33(1) of the Drugs and Cosmetics Act, 1940, vide notification G.S.R. 756(E), dated 16 October 2025 — with copies made available to the public on 28 October 2025 and a thirty-day window for objections and suggestions. After considering the feedback received and consulting the Drugs Technical Advisory Board (DTAB) as required under Section 12, the Central Government has now finalised the rules as G.S.R. 706(E), styled the Drugs (Eleventh Amendment) Rules, 2026, published in the Gazette of India (Extraordinary, Part II, Section 3(i), No. 642) on 5 August 2026.
Prior to this amendment, a Licensing Authority’s response to fabricated or misleading submissions was largely confined to rejecting the specific application or, where a licence had already been granted, cancelling it. Debarment — a forward-looking bar on an applicant’s ability to file further applications — did not exist as a codified concept anywhere in the Drugs Rules, 1945 until now.
02What “debarment” now means
Rule 2, sub-rule (bb), inserted after sub-rule (b), defines the term for the first time across the Rules.
“Debarment” means the prohibition, exclusion, or disqualification of any person, firm, or entity from engaging in the import of drugs, manufacture for sale or for distribution, sell, stock or exhibit or offer for sale, or distribute, for a specified period or permanently, as a consequence of the violation of statutory provisions.
03Scope: seven insertions across the Rules
An operative debarment rule, near-identical in wording, has been inserted at seven points in the Drugs Rules, 1945, extending the mechanism across the import, manufacturing, licence-cancellation, new drug/clinical trial, and medical device licensing provisions, among others governed by the respective Parts.
| New rule | Inserted after | Appeal (sub-rule 2) |
|---|---|---|
| 29B | Rule 29A | Yes |
| 66B | Rule 66A | Yes |
| 84F | Rule 84E | Yes |
| 93A | Rule 93 | Yes |
| 122DBA | Rule 122DB | Not provided |
| 122Q | Rule 122P | Yes |
| 150L | Rule 150K | Yes |
Rule 122DBA is the sole insertion drafted as a single operative paragraph, with no corresponding sub-rule (2) appeal clause — unlike the other six insertions, which each carry an identical thirty-day appeal provision. Whether this is a deliberate drafting choice or an oversight is not stated in the notification; applicants affected under this specific insertion should seek independent legal confirmation of their appeal rights rather than assume parity with the other six Parts.
04Procedure for debarment
Finding of non-compliance
The Licensing Authority — or, depending on the Part, the Central Licensing Approving Authority — determines that the applicant, or any other person acting on the applicant’s behalf, is guilty of submitting misleading, fake, or fabricated documents or information.
Opportunity to show cause
Before any order is passed, the applicant must be given an opportunity to show cause, with reasons for the order recorded in writing.
Debarment order
The authority may debar the applicant for such period as it considers fit — the Rules place no outer limit, so the period, including a permanent bar, is left to the authority’s discretion.
Right of appeal (six of seven insertions)
An aggrieved applicant may appeal to “that Government” within thirty days of receiving the order. The Government may conduct an inquiry as it considers necessary, provide an opportunity of being heard, and pass such orders as it deems appropriate. This safeguard is absent from the Rule 122DBA insertion — see Section 03 above.
05Compliance implications
Documentation must be independently verifiable
Supporting documents, certifications, test data, and third-party reports submitted with any licence application should be capable of independent verification prior to filing — the bar applies to the applicant even where the fabrication originates with “any other person” acting on the applicant’s behalf.
Extended exposure to consultants and intermediaries
Because the provision explicitly covers submissions made by any person on the applicant’s behalf, regulatory affairs consultants, testing laboratories, and other intermediaries preparing dossiers should treat this as a shared compliance obligation, not solely the applicant’s.
Material commercial consequence
A debarment order restricts an entity’s ability to file future applications under the affected Part — with direct implications for continuity of licensed operations, new product launches, or licence renewals during the debarment period.
Procedural safeguards remain — with one gap
The show-cause requirement is uniform across all seven insertions, and the thirty-day appeal window applies to six of them. Entities operating under provisions governed by Rule 122DB (new drugs / clinical trials) should specifically confirm their appeal recourse, since the parallel appeal clause is not present in Rule 122DBA as notified.
How Vaayath can help
Vaayath Consulting supports pharmaceutical, medical device, cosmetics, and nutraceutical companies with dossier preparation, GMP/QMS documentation integrity, and regulatory filings across CDSCO’s import, manufacturing, and new drug approval pathways — including pre-submission verification designed to withstand this heightened scrutiny standard. For a documentation-integrity review ahead of your next filing, reach out.
info@vaayath.com
Pharminho perspective
This amendment formalises a standard regulated entities should already be applying: documentation submitted in support of a licence must be accurate, verifiable, and defensible. The one open question — the missing appeal clause under Rule 122DBA — is worth watching for a possible corrigendum. Pharminho will continue to track developments under the Drugs and Cosmetics Act, 1940, and the rules made thereunder.
PHARMINHO REGULATORY DESK
